English  |  中文
Please enter exact key words
PTG-01

PTG-01 is now in phase I clinical stage. Our preliminary data
has proved it’s both safe and efficient.

Home / Pipeline / PTG-01

PTG-01 is a Chimeric antigen receptor (CAR) T cell product that targets CD19 which is found on the surface of almost all B-cell leukemias and lymphomas. PTG-01 uses our proprietary CAR T technology and is composed of a humanized anti-CD19 single-chain variable fragment (scFv) linked by a hinge and transmembrane domain and the intracellular 4-1BB and CD3ζ co-stimulatory domain. The intracellular domains are activated when the CAR T cells bind to the CD19+ cancer cells, thus to kill cancer cells by T cell-mediated cytotoxicity.

Status

PTG-01 is now in phase I clinical stage. Our preliminary data has proved it’s both safe and efficient.

Mechanism of Action

For PTG-01, we used the technology to engineer the patients’ own T-cells by artificially equipping them with chimeric antigen receptors (CARs) which then enable them to bind to CD19 on the surface of B-cell leukemias and lymphomas. The engineered T cells kill their targets by programming them to undergo apoptosis.

About the Target

• CD19 is expressed on the surface of most B-cell malignancies
• Antibodies against CD19 inhibit growth of tumor cells
• CD19 expression is restricted to B cells and their precursors
• CD19 is not expressed on pluripotent bone marrow stem cells
• On-target expected SE is B-cell aplasia

PTG-01

About ALL

Acute lymphocytic leukemia (ALL) is a type of cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. ALL is characterized by an overproduction of immature white blood cells, called lymphoblasts or leukaemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to function properly to prevent or fight infection. Inadequate numbers of red cells and platelets being made by the marrow cause anaemia, and easy bleeding and bruising. Acute lymphocytic leukemia is the most common type of cancer in children, and treatments result in a good chance for a cure. Acute lymphocytic leukemia can also occur in adults, though the chance of a cure is greatly reduced.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry
Diane Hong Business Development Manager
1-516-927-7606
info@protheragen.com
Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118
Email: info@protheragen.com

Opening Hours

Monday — Sunday: 9am — 6pm